Investigational drug · Phase 2
TRK-950
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "TRK-950"
First trial start
2022
Jul 6, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRK-950", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Adenocarcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Solid Tumor
- Melanoma
Approved drugs for the same conditions: Melanoma · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TRK-950" as an intervention, largest first.
- A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerPivotal-lookingRecruiting
Toray Industries, IncIndustry
NCT06038578 · 146 participants (planned) · Start Oct 4, 2023 · Primary completion Oct 31, 2027
Drug: TRK-950; Ramucirumab and 1 more · For: Gastric Adenocarcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Duarte, California; Irvine, California; Santa Monica, California · 27 sites in all
Toray Industries, IncIndustry
NCT03872947 · 138 participants · Start Apr 26, 2019 · Primary completion Jul 16, 2026
Drug: TRK-950; TRK-950 and 14 more · For: Solid Tumor; Colorectal Cancer; Cholangiocarcinoma and 9 more
Sites: Scottsdale, Arizona; Tucson, Arizona; Los Angeles, California · 14 sites in all
Toray Industries, IncIndustry
NCT05423262 · 49 participants (planned) · Start Jul 6, 2022 · Primary completion Mar 31, 2028
Drug: TRK-950; TRK-950 and 3 more · For: Solid Tumor; Melanoma
Sites: Nagoya, Japan; Fukuoka, Japan; Sapporo, Japan · 10 sites in all
Toray Industries, IncIndustry
NCT02990481 · 38 participants · Start Mar 6, 2017 · Primary completion Sep 16, 2019
Drug: TRK-950; TRK-950 and 1 more · For: Locally Advanced or Metastatic Solid Carcinomas; Colon Cancer; Cholangiocarcinoma
Sites: Phoenix, Arizona; Scottsdale, Arizona; Lyon, France
Newest research
PubMed records naming it or its code names, newest first.
- A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Koyama T, Yonemori K, Sato J, et al. · Invest New Drugs 2026
- Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors.
Cassier PA, Borad MJ, Sharma S, et al. · Cancer Res Commun 2025
- Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody.
Majima Y, Kryza D, Sanada M, et al. · J Cancer Res Clin Oncol 2025
- Development and validation of an antidrug antibody assay for TRK-950 using Melonࡊ gel and SPEAD pretreatment.
Nishio R, Nakanaga K, Yoshinaga R, et al. · Bioanalysis 2025
- Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950.
Okano F, Saito T, Minamida Y, et al. · Cancer Res Commun 2023
Also in development for Gastric Adenocarcinoma
- QLS31905Phase 35 trials
Qilu Pharmaceutical Co., Ltd. · Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma
- ASKB589Phase 33 trials
AskGene Pharma, Inc. · Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor
- ASP2138Phase 31 trial
Astellas · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- DenikitugGS-1811, DENPhase 22 trials
Gilead Sciences · Advanced Microsatellite Stable Colorectal Cancer, HER2-negative, Gastroesophageal Junction
- BHB810Phase 21 trial
BigHat Biosciences, Inc. · Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.